Beruflich Dokumente
Kultur Dokumente
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Ammonul
(Medicis)
Asacol HD
(Warner Chilcott)
Cordran SP
(Aqua)
Crestor
(AstraZeneca)
Delalutin
(Bristol-Myers Squibb)
Diabeta
(Sanofi Aventis)
Doryx
(Mayne)
Enablex
(Novartis)
Exelon
(Novartis)
Fenoglide
(Santarus)
Frova
(Endo)
Fusilev
(Spectrum)
Sodium benzoate/Sodium
phenylacetate
Mesalamine delayed-release tablet
Trigen (Ailex)
Zydus
Cintex (Teligent)
Rosuvastatin calcium
Impax (CorePharma)
Mylan
Alvogen
Mylan
Frovatriptan
Levoleucovorin 50 mg/vial
West-Ward (Eurohealth)
Hydroxyprogesterone caproate
injection (brand discontinued)
Glyburide
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Gleevec
(Novartis)
Glumetza
(Santarus)
Glyset
(Pharmacia & Upjohn)
Imitrex
(GlaxoSmithKline)
Integrilin
(Schering)
Intermezzo
(Purdue)
Lodosyn
(Aton)
Naftin
(Merz)
Nasonex
(Merck)
Neoprofen
(Recordati Rare)
Nilandron
(Concordia)
Nuvigil
(Teva)
Oxistat
(Fougera)
Tikosyn
(Pfizer)
Trizivir
(GlaxoSmithKline)
Voltaren
(GlaxoSmithKline)
Imatinib
Lupin
Miglitol tablets
Sun (Orient)
Lannett
Eptifibatide
Gavis (Novel)
Carbidopa
Naftifine 2% cream
Apotex
Ibuprofen lysine
X-Gen (Exela)
Nilutamide
ANI Pharmaceuticals
Armodafinil
Mylan
Oxiconazole 1% cream
Taro
Dofetilide
Mayne (Tiger)
Lupin
Diclofenac 1% gel
Amneal
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Zegerid
(Santarus)
Zegerid OTC
(Bayer)
Ziana
(Medicis)
Cubicin
(Cubist)
Edecrin
(Aton)
Epzicom
(GlaxoSmithKline)
Zegerid
(Santarus)
Remicade
(Janssen)
Azor
(Daiichi Sankyo)
Benicar/Benicar HCT
(Daiichi Sankyo)
Omeprazole/Sodium bicarbonate
capsule
Omeprazole/Sodium bicarbonate
capsule
Clindamycin phosphate 1.2%/
Tretinoin 0.025%
Daptomycin
Teva (Actavis)
Edenbridge
Abacavir sulfate/Lamivudine
600 mg/300 mg tablet
Omeprazole/Sodium bicarbonate
suspension
Infliximab
September 201690
Hospira (biosimilari)
Olmesartan/Amlodipine
October 2016
Olmesartan/Olmesartan HCTZ
October 201624
Seroquel XR
(AstraZeneca)
Kaletra
(Abbott)
Lantus
(Sanofi-Aventis)
Insulin glargine
November 20162
December 20169,36,137
December 2016109 (This product
will be a new brand of insulin
glargine [Basaglar], not a generic.)
More. . .
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Norvir
(Abbvie)
ProAir HFA
(Teva)
Relpax
(Pfizer)
Aggrenox
(Boehringer Ingelheim)
Azilect
(Teva)
Tamiflu
(Genentech)
Minastrin 24 Fe
(Warner Chilcott)
Pristiq
(Wyeth)
Vytorin
(Merck)
Zetia
(Merck)
Strattera
(Lilly)
Adcirca
(Lilly)
Prezista
(Janssen)
Reyataz
(Bristol-Myers Squibb)
Sustiva
(Bristol-Myers Squibb)
December 20169,137
Albuterol
Perrigof,34
December 201634
Eletriptan
December 201624
Aspirin/Dipyridamole
Teva
Oseltamivir capsules
Natco
Ethinyl estradiol/Norethindrone
acetate/Ferrous fumarate
Desvenlafaxine succinate
extended-release tablet
Ezetimibe/Simvastatin
Lupin
March 2017151
March 201733
Ezetimibe
April 201712,140
Atomoxetine
May 2017
Tadalafil
November 201718
Darunavir tablet
November 201779
Atazanavir
December 201752
Efavirenz
December 201724
April 201728,134
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Truvada
(Gilead)
Viagra
(Pfizer)
Emtricitabine/Tenofovir
disoproxil fumarate tablet
Sildenafil
December 201725
Viread
(Gilead)
Copaxone
(Teva)
Solodyn
(Medicis)
Treximet
(Pozen)
Factive
(Cornerstone)
Sensipar
(Amgen)
Enbrel
(Amgen)
Lexiva
(Vertex)
Remodulin
(United Therapeutics)
Acanya
(Valeant)
Clolar
(Genzyme)
Emend
(Merck)
Latuda
(Sunovion)
Minocycline extended-release
tablet 55 mg, 65 mg, 80 mg,
105 mg, 115 mg
Sumatriptan/Naproxen
Gemifloxacin tablet
February 2018102
March 201829
Cinacalcet tablet
March 201851
Etanercept
Sandoz (biosimilar1)
Fosamprenavir
Lupin, Mylan
June 2018d,130
Treprostinil injection
Sandoz
Actavis
July 2018d
Aprepitant capsule
Sandoz
July 2018e,113
Lurasidone
July 2018d
More. . .
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Atripla
(Gilead)
Aloxi
(Eisai)
Levitra
(GlaxoSmithKline)
Vesicare
(Astellas)
Finacea
(Bayer)
Fortesta
(Endo)
Lyrica
(Pfizer)
Efavirenz/Emtricitabine/Tenofovir
disoproxil fumarate
Palonosetron injection
August 2018e,68
Vardenafil tablet
Solifenacin succinate
Actavis, Teva
October 201820
Azelaic acid
Glenmark
November 2018
Testosterone gel
Actavis
November 2018d,65
Pregabalin
December 201850
Zyclara
(Medicis)
Ranexa
(Gilead)
AzaSite
(InSite Vision)
Emend
(Merck)
Faslodex
(AstraZeneca)
Exjade
(Novartis)
Sporanox
(Janssen)
Imiquimod cream
Ranolazine
Lupin, Teva
February 201981
Azithromycin 1% ophthalmic
solution
Fosaprepitant injection
Mylan,f,13 Sandoz
March 2019e,13,43
March 201935
Fulvestrant
Sandozf,144
March 2019144
Actavis, Mylanh,11
April 2019d
Ferah,132
June 2019d
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Uloric
(Takeda)
Edluar
(Orexo)
Fentora
(Cephalon)
Treanda
(Teva)
Daliresp
(AstraZeneca)
Namenda XR
(Forest)
Silenor
(Somaxon)
Vigamox
(Alcon)
Delzicol
(Warner Chilcott)
Safyral
(Bayer)
Chantix
(Pfizer)
Dexilant
(Takeda)
Lialda
(Shire)
Absorica
(Ranbaxy)
Ofirmev
(Mallinckrodt)
Febuxostat
June 2019d,16
September 2019e,154.155
October 201972
November 2019111
Memantine extended-release
capsule
Doxepin
Moxifloxacin ophthalmic
March 2020e,6
Mesalamine delayed-release
capsule
Drospirenone/Ethinyl
estradiol/Levomefolate calcium
Varenicline
Mylanh,115
April 2020d
Actavis
April 2020d,46
May 2020d,49
Dexlansoprazole
June 2020104
Isotretinoin
Actavisf,88
Acetaminophen injection
January 2020156
January 20203
June 202042,145
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Latisse
(Allergan)
Sutent
(Pfizer)
Tarceva
(OSI)
Diclegis
(Duchesnay)
Perforomist
(Mylan)
Bystolic
(Forest)
Bimatoprost 0.03%
Apotex, Sandoz
January 202145
Sunitinib
Mylan
February 2021
Erlotinib tablet
Mylan
May 2021e,141
Doxylamine/Pyridoxine
Actavis
June 2021e,158
Teva
June 2021
Nebivolol
Emtriva
(Gilead)
Brovana
(Sunovion)
Revlimid
(Celgene)
Vimpat
(UCB)
Emtricitabine capsule
September 2021d,4
Arformoterol
Teva
November 2021
Lenalidomide
Allerganf,23
March 202223
Lacosamide
March 20225
Zipsor
(Depomed)
Alimta
(Lilly)
Banzel
(Eisai)
Actavis,f,95 Biopharma
May 2022d
Viibryd
(Forest)
Vilazodone
Teva
June 2022d,21
Rufinamide
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Januvia
(Merck)
Toviaz
(Pfizer)
Sitagliptin
July 2022d,21,124
Fesoterodine extended-release
tablet
July 2022d,82,147
Pralatrexate
November 2022149
Maraviroc
Hetero
November 2022d,21
Sodium oxybate
December 2022d,7
Prasugrel
January 2023d
Naproxen/Esomeprazole
magnesium delayed-release tablet
Lisdexamfetamine
February 2023d,77
Paddock
March 2023
Strides Arcolab
April 2023
Gabapentin
Pitavastatin
February 2024d
May 2024d
June 2025d,125
Dasatinib
Apotex
March 2026e,152
Folotyn
(Spectrum)
Selzentry
(Pfizer)
Xyrem
(Jazz)
Effient
(Eli Lilly)
Vimovo
(Horizon)
Vyvanse
(Shire)
Suprep
(Braintree)
Edurant
(Janssen)
Gralise
(Depomed)
Livalo
(Kowa)
Pataday
(Alcon)
Nucynta
(Depomed)
Sprycel
(Bristol-Myers Squibb)
February 202355
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Janumet
(Merck)
Janumet XR
(Merck)
Natazia
(Bayer)
Aplenzin
(Valeant)
Cambia
(Depomed)
Nuedexta
(Avanir)
AndroGel 1.62%
(AbbVie)
Ampyra
(Acorda)
Lumigan
(Allergan)
Epiduo
(Galderma)
Fanapt
(Vanda)
Nexavar
(Bayer)
Oracea
(Galderma)
Promacta
(Novartis)
Sitagliptin/Metformin
April 2026d,21
Anchen, Teva
April 2026d,21
May 2026d,61
Bupropion hydrobromide
extended-release tablet
Diclofenac potassium oral
solution 50 mg
Dextromethorphan/Quinidine
June 2026e,83
Par
June 2026e,150
Testosterone
Actavis,h,44 Perrigo
October 2026d
Dalfampridine extended-release
tablet
Bimatoprost ophthalmic solution
0.01%
Adapalene 0.1%/Benzoyl
peroxide 2.5%
Iloperidone
July 2027e,131
Inventia, Roxanef,157
November 2027157
Sorafenib
Mylan
December 2027d,21
Doxycycline 40 mg capsule
December 2027110
Eltrombopag
Hetero
February 2028d,21
Differin
(Galderma)
Call (Rochester)
May 2028
June 2027123
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Canasa
(Aptali)
Nucynta ER
(Depomed)
Onglyza
(Bristol-Myers Squibb)
Staxyn
(Bayer)
Pennsaid
(Horizon)
Colcrys
(Takeda)
Lo Loestrin Fe
(Actavis)
Tygacil
(Wyeth)
Isentress
(Merck)
Quartette
(Teva)
Moxeza
(Alcon)
Qsymia
(Vivus)
Savella
(Forest)
Tykerb
(Novartis)
Travatan Z
(Alcon)
Suboxone
(Reckitt Benckiser)
Mylan, Sandoz
June 2028d,133
Tapentadol extended-release
tablet
Saxagliptin
Actavis
September 2028d,125
November 2028d
December 202840
Colchicine
February 2029d
Ethinyl estradiol/Norethindrone
acetate/Ferrous fumarate
Tigecycline injection
February 2029e,32
February 202974
Raltegravir tablet
Hetero
March 2029d,21
Levonorgestrel/Ethinyl estradiol
Lupin
March 2029d,21
Lupin
May 2029d,6
Phentermine/Topiramate
extended-release capsule
Milnacipran
Actavish,41
June 2029d
October 2029d,128
Actavish,86
March 2030d
Lapatinib
Travoprost 0.004% ophthalmic
solution
Buprenorphine/Naloxone
sublingual film
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Jevtana
(Sanofi Aventis)
Giazo
(Valeant)
Multaq
(Sanofi-Aventis)
Contrave
(Orexigen)
Zubsolv
(Orexo)
Alocril
(Allergan)
Avandamet
(SB Pharmco)
Avandaryl
(SB Pharmco)
Avandia
(SB Pharmco)
Axiron
(Eli Lilly)
Cabazitaxel
Breckenridgeh,54
October 2030d
June 2031e,75
Dronedarone
June 2031
Bupropion/Naltrexone sustained
release tablet
Buprenorphine/Naloxone
sublingual tablet
Nedocromil ophthalmic
Actavish,114
January 2032d
Actavish,84
September 2032d
Akorn
Uncertaing
Rosiglitazone/Metformin
Teva
Rosiglitazone/Glimepiride
Teva
Rosiglitazone
Uncertain27
Bloxiverz
(Eclat)
CellCept
(Roche Palo)
Exalgo
(Mallinckrodt)
Exelon
(Novartis)
Neostigmine
Eurohealth
Mycophenolate mofetil
hydrochloride injection
Hydromorphone extended-release
tablet 32 mg
Rivastigmine oral solution (brand
discontinued)
Bedford Labs
Uncertaing
Actavis, Osmotica
Uncertaing
Ranbaxy
Oxytrol
(Actavis)
Teva
Uncertain37
More. . .
Branda
(Manufacturer)
Generic Name
Generic Manufacturer(s)b,1
Anticipated Availabilityc
Prandimet
(Novo Nordisk)
Renagel
(Genzyme)
Renvela
(Genzyme)
Rezira
(Hawthorn)
Repaglinide/metformin tablet
Lupin
Uncertaing
Impaxf,15
Impaxf,15
Uncertaing
Uncertaing
Sarafem
(Apil)
Welchol
(Daiichi Sankyo)
Fluoxetine tablet
Teva
Uncertaing
Uncertain22,59
a.
b.
c.
d.
e.
f.
g.
h.
i.
Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical
judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national
organizations. Information and internet links in this article were current as of the date of publication.
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
References
1.
Drugs@FDA.
FDA approved drug products.
http://www.accessdata.fda.gov/Scripts/cder/DrugsatF
DA/index.cfm. (Accessed August 31, 2016).
2. Voreacos D, Decker S. AstraZeneca wins ruling on
extended-release Seroquel patent. March 29, 2012.
http://www.bloomberg.com/news/articles/2012-0329/astrazeneca-wins-ruling-on-extended-releaseseroquel-patent-1-. (Accessed August 21, 2016).
3. Anon. Allergan announces agreement with Amneal
related to Namenda XR patent litigation. September
10,
2015.
http://www.allergan.com/news/news/thomsonreuters/allergan-announces-agreement-with-amnealrelated-t. (Accessed August 29, 2016).
4. Leuty R. Why a low-price generic of this HIV drug
may not hit the U.S. market soon. July 21, 2016.
http://www.bizjournals.com/sanfrancisco/blog/biotech
/2016/07/gilead-sciences-hiv-aids-gild-emtrivaaurobindo.html. (Accessed August 26, 2016).
5. Vergauwen W. Delaware court backs UCB drug
patent, shares jump.
August 15, 2016,
http://www.reuters.com/article/us-ucb-sa-rulingidUSKCN10Q0O1?feedType=RSS&feedName=healt
hNews&utm_source=feedburner&utm_medium=feed
&utm_campaign=Feed%3A+reuters%2FhealthNews
+%28Reuters+Health+News%29. (Accessed August
15, 2016).
6. Anon.
Settlement and dismissal of patent
infringement case secured for SSJR client Lupin.
October
8,
2013.
https://www.ssjr.com/articles/view/213.
(Accessed
August 24, 2016).
7. Anon.
Amneal, Par, and Roxane challenge
distribution patent for Xyrem under AIA covered
business method review.
June 24, 2015.
http://www.bigmoleculewatch.com/2015/06/24/amne
al-par-and-roxane-challenge-distribution-patent-forxyrem-under-aia-covered-business-method-review/.
(Accessed August 26, 2016).
8. Anon. Gilead, Teva reach settlement in Viread
patent
lawsuit.
February
19,
2013.
http://www.reuters.com/article/2013/02/20/us-gileadteva-idUSBRE91J05920130220. (Accessed August
22, 2016).
9. Renoe J. The major pharmaceuticals losing patent
protection in 2016.
December 16, 2015.
http://blog.dicksondata.com/2015/12/drugs-losingpatent-protection/. (Accessed August 21, 2016).
10. DeGiulio J. . Biotech/Pharma Docket. November
23,
2011.
http://www.patentdocs.org/2011/11/biotechpharmadocket.html. (Accessed August 23, 2016).
11. Anon.
Novartis accuses Mylan of patent
infringement.
July
16,
2014.
http://www.firstwordpharma.com/node/1224755#axzz
47Qzsz239. (Accessed August 23, 2016).
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
%20Generic_Pristiq_2015-0702.pdf.
(Accessed
August 26, 2016).
Alexander A. Teva reaches settlement in ProAir
HFA
patent
case.
June
20,
2014.
http://www.drugstorenews.com/article/teva-reachessettlement-proair-hfa-patent-case.
(Accessed
August 21, 2016).
Merck Sharp & Dohme Corp. v. Sandoz Inc. Case
No. 3:12-cv-03289-PGS-LHG. August 27, 2015.
http://www.leagle.com/decision/In%20FDCO%20201
50828906/Merck%20Sharp%20&%20Dohme%20Co
rp.%20v.%20Sandoz%20Inc. (Accessed August 23,
2016).
United States District Court for the Northern District
of Illinois.
Abbott Laboratories vs Matrix
Laboratories, Inc., Matrix Laboratories, LTD, Mylan
Inc. Memorandum in support of defendants motion
to
stay.
May
22,
2009.
http://www.fdalawblog.net/files/matrix---motion-tostay.pdf. (Accessed August 21, 2016).
Anon. Watson and Barr settle lawsuit over Oxytrol.
October
29,
2009.
http://www.pharmaceuticalonline.com/doc/watsonand-barr-settle-lawsuit-over-oxytrol-0001. (Accessed
August 29, 2016).
Anon. Generic competitors regulatory issues prompt
stay of Lialda patent litigation. August 13, 2015.
http://www.flhlaw.com/stay-lialda-litigation/.
(Accessed August 24, 2016).
Anon.
Somaxon Pharmaceuticals announces
settlement of Silenor patent litigation with Actavis.
February
5,
2013.
http://www.globenewswire.com/newsrelease/2013/02/05/521096/10020662/en/SomaxonPharmaceuticals-Announces-Settlement-of-SilenorPatent-Litigation-With-Actavis.html.
(Accessed
August 24, 2016).
DAnnunzio P.J. Bayer erectile dysfunction drug
patents valid, judge rules.
May 5, 2016.
http://www.thelegalintelligencer.com/id=1202756821
784/Bayer-Erectile-Dysfunction-Drug-Patents-ValidJudge-Rules?slreturn=20160723113004. (Accessed
August 23, 2016).
Anon. Vivus announces favorable Markman ruling in
Qsymia patent litigation.
July 21, 2016.
http://www.marketwired.com/press-release/vivusannounces-favorable-markman-ruling-in-qsymiarpatent-litigation-nasdaq-vvus-2144589.htm.
(Accessed August 27, 2016)
Banerjee A. Shire gets favorable ruling against
Allergan in Lialda patent case. March 28, 2016.
http://news.yahoo.com/shire-gets-favorable-rulingagainst-allergan-lialda-patent-160201632-finance.html. (Accessed August 24, 2016).
Davis R. Fed. Circ. affirms Sandoz loss in generic
AzaSite
case.
April
9,
2015.
http://www.law360.com/articles/641282/fed-circaffirms-sandoz-loss-in-generic-azasite-case.
(Accessed August 23, 2016).
Anon. Actavis confirms generic AndroGel 1.62%
patent
challenge.
April
1,
2013.
http://www.prnewswire.com/news-releases/actavis-
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
with-bms-merck-over-hiv-drug-generic-plans.
(Accessed August 26, 2016).
Anon. Indiana patent litigation: Lilly files new lawsuit
alleging patent infringement of Alimta. August 10,
2015.
http://www.iniplaw.org/2015/08/indianapatent-litigation-lill-8.html.
(Accessed August 26,
2016).
Anon.
More generics makers targeting Tevas
Copaxone 40 mg.
September 8, 2014.
http://www.fdanews.com/articles/166954-moregenerics-makers-targeting-tevas-copaxone-40-mg.
(Accessed August 26, 2016).
Anon. Watson confirms Welchol oral suspension
patent
challenge.
January
25,
2011.
http://www.prnewswire.com/news-releases/Watsonconfirms-welchol-oral-suspension-patent-challenge114594049.html. (Accessed August 31, 2016).
Decker S. Actavis wins patent appeal for generic to
Tevas
Fentora.
February
14,
2013.
http://www.bloomberg.com/news/articles/2013-0214/actavis-wins-appeal-over-two-patents-for-teva-sfentora-drug-1-. (Accessed August 29, 2016).
nd
Wilson D. AbbVie hits Hetero USA with 2 suit over
Norvir
generic.
April
25,
2014.
http://www.law360.com/articles/531891/abbvie-hitshetero-usa-with-2nd-suit-over-norvir-generic.
(Accessed August 21, 2016).
United States Court of Appeals for the Federal
Circuit. Apotex Inc., appellant vs Wyeth LLC,
appellee. 2015-1871. Appeal from the United States
Patent and Trademark Office, Patent Trial and
Appeal Board in No. IPR2014-00115.
Decided
August
16,
2016.
http://www.cafc.uscourts.gov/sites/default/files/opinio
ns-orders/15-1871.Opinion.8-11-2016.1.PDF.
(Accessed August 20, 2016).
Food and Drug Administration. ANDA approval
letter. Par generic Giazo. September 8, 2015.
http://www.accessdata.fda.gov/drugsatfda_docs/appl
etter/2015/206336Orig1s000ltr.pdf.
(Accessed
August 29, 2016).
Feeley J, Gerlin A. Shire faces patent suit revival
over Lialda colitis drug.
February 28, 2014.
http://www.bloomberg.com/news/articles/2014-0228/shire-faces-patent-suit-revival-over-lialda-colitisdrug. (Accessed August 24, 2016).
Zagger Z. AstraZeneca sues 4 drugmakers to stop
generic
Vimovo.
October
25,
2013.
http://www.law360.com/articles/483202/astrazenecasues-4-drugmakers-to-stop-generic-vimovo.
(Accessed August 26, 2016).
Anon.
Helsinn reaches settlement agreement
regarding patent dispute on Aloxi. January 12, 2015.
http://www.prnewswire.com/news-releases/helsinnreaches-settlement-agreement-regarding-patentdispute-on-aloxi-288224391.html. (Accessed August
22, 2016).
Weinberg D.
Will patent cliff concerns impact
Johnson
&
Johnson?
July
7,
2015.
http://www.fool.com/investing/general/2015/07/07/will
-patent-cliff-concerns-impact-johnson-johnson.aspx.
(Accessed September 9, 2016).
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
2477168_apxpfizergenericviagra.html.
(Accessed
August 22, 2016).
92. Koppala AR. Mylan settles Viagra patent litigation
with
Pfizer.
April
13,
2015.
http://www.reuters.com/article/2015/04/13/us-mylanlitigation-pfizer-idUSKBN0N423K20150413.
(Accessed August 22, 2016).
93. Anon. TWi announces settlement with Takeda on
Dexilant
litigation.
April
27,
2015.
http://www.prnewswire.com/news-releases/twiannounces-settlement-with-takeda-on-dexilantrlitigation-300072295.html. (Accessed August 24,
2016).
94. Koenig B. Dr. Reddys files first paragraph IV ANDA
against Tevas 40 mg Copaxone. August 15, 2014.
http://www.fdanews.com/articles/166376-dr-reddysfiles-first-paragraph-iv-anda-against-tevas-40mgcopaxone?v=preview. (Accessed August 26, 2016).
95. Depomed settles Zipsor patent litigation with Watson
Laboratories.
June
4,
2015.
http://www.pharmabiz.com/NewsDetails.aspx?aid=88
666&sid=2. (Accessed August 26, 2016).
96. Zacks Equity Research. Acorda gets favorable court
ruling in Ampyra patent lawsuit. March 22, 2016
http://finance.yahoo.com/news/acorda-getsfavorable-court-ruling-183006905.html.
(Accessed
August 27, 2016).
97. Wilson D. Teijin, Takeda accuse Lupin of infringing
Uloric
patent.
February
12,
2014.
http://www.law360.com/articles/509602/teijin-takedaaccuse-lupin-of-infringing-uloric-patent.
(Accessed
August 23, 2016).
98. Anon. Depomed announces settlements with two
Gralise
ANDA
filers.
April
14,
2014.
http://www.biotechnologyevents.com/node/4855.
(Accessed August 26, 2016).
99. Anon. Actavis confirms generic Onglyza patent
challenge.
May
27,
2014.
http://www.prnewswire.com/news-releases/actavisconfirms-generic-onglyza-patent-challenge260817921.html. (Accessed August 27, 2016).
100. Anon. Alcon sues Wockhardt for patent infringement
of
Pataday.
September
25,
2013.
http://www.iniplaw.org/2013/09/alcon-sueswockhardt-for-paten.html.
(Accessed August 26,
2016).
101. Anon. Genzyme hits Sun with suit over generic
leukemia
drug.
March
24,
2016.
https://www.lexisnexis.com/legalnewsroom/litigation/
b/newsheadlines/archive/2016/03/24/genzyme-hitssun-with-suit-over-generic-leukemiadrug.aspx?Redirected=true. (Accessed August 22,
2016).
102. Anon. Pozen patents upheld in Treximet patent
litigation.
August
8,
2011.
http://www.businesswire.com/news/home/201108080
05396/en/Pozen-Patents-Upheld-Treximet-PatentLitigation#.U4XyBn7D-1s. (Accessed August 22,
2016).
103. Anon. Avanir, Sandoz settle Nuedexta patent suit.
August 14, 2013.
http://www.drugs.com/news/
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
and-nucynta-er-patent-litigation.html.
(Accessed
August 27, 2016).
126. Kass D. Sandoz, UTC settle generic Remodulin
patent
suit.
September
30,
2015.
http://www.law360.com/articles/709188/sandoz-utcsettle-generic-remodulin-patent-suit.
(Accessed
August 31, 2016).
127. Shine J. Glenmark settles patent war over Savella.
December 21, 2015.
http://www.livemint.com/
Companies/OYBtDHxTAbNVlp3RYOkCCI/Glenmarksettles-patent-war-over-Savella.html.
(Accessed
August 27, 2016).
128. Food and Drug Administration. ANDA approval
letter. Apotex generic Travatan Z. July 10, 2016.
http://www.accessdata.fda.gov/drugsatfda_docs/appl
etter/2015/203431Orig1s000ltr.pdf.
(Accessed
August 29, 2016).
129. Kass D. Valeant hits Apotex with patent suit over
colitis drug.
October 1, 2015.
http://www.law
360.com/articles/709788/valeant-hits-apotex-withpatent-suit-over-colitis-drug. (Accessed August 29,
2016).
130. James B. ViiV, Vertex sue over Mylans bid to
market generic Lexiva.
August 24, 2012.
http://www.law360.com/articles/372465/viiv-vertexsue-over-mylan-s-bid-to-market-generic-lexiva.
(Accessed August 22, 2016).
131. Davis R. Galderma, Actavis settle generic Epiduo
suit ahead of trial. April 13, 2015. http://www.law
360.com/articles/642310/galderma-actavis-settlegeneric-epiduo-suit-ahead-of-trial.
(Accessed
August 27, 2016).
132. Anon. Par Pharmaceutical acquires rights to market
and distribute generic Dexilant in the U.S. April 19,
2012.
https://www.thestreet.com/story/11501680/2/parpharmaceutical-acquires-rights-to-market-anddistribute-generic-dexilant-in-the-us.html. (Accessed
August 24, 2016).
133. Anon. Mylan confirms first-to-file patent challenge
relating
to
Canasa.
July
11,
2013.
http://www.prnewswire.com/news-releases/mylanconfirms-first-to-file-patent-challenge-relating-tocanasa-215055171.html.
(Accessed August 27,
2016).
134. Voreacos D, Decker S. Teva wont sell generic
Vytorin until 2017 under accord. July 8, 2011.
http://www.bloomberg.com/news/articles/2011-0708/teva-won-t-sell-generic-vytorin-until-2017-settlingmerck-patent-lawsuit. (Accessed August 22, 2016).
135. Anon.
Sunovion Pharmaceuticals files patent
infringement lawsuits regarding Latuda. January 14,
2015.
http://www.pharmpro.com/news/2015/01/sunovionpharmaceuticals-files-patent-infringement-lawsuitsregarding-latuda%C2%AE. (Accessed August 22,
2016).
136. Anon. Aurobindo Pharma lands in patient litigation
cases
in
USA.
April
28,
2014.
http://articles.economictimes.indiatimes.com/201404-28/news/49464640_1_aurobindo-pharma-patentinfringement-hospira. (Accessed August 26, 2016).
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
http://www.law360.com/articles/505154/eli-lilly-suespar-pharma-to-block-generic-effient.
(Accessed
August 26, 2016).
149. Anon. Spectrum Pharmaceuticals settles Folotyn
(pralatrexate injection) ANDA patent litigation. July
13, 2016. http://finance.yahoo.com/news/spectrumpharmaceuticals-settles-folotyn-pralatrexate110000957.html. (Accessed August 26, 2016).
150. Food and Drug Administration. ANDA approval
letter.
Mylan generic Cambia.
May 2, 2016.
http://www.accessdata.fda.gov/drugsatfda_docs/appl
etter/2016/202964Orig1s000ltr.pdf.
(Accessed
August 31, 2016).
151. OptumRx.
Minastrin 24 Fe (norethindrone
acetate/ethinyl estradiol/ferrous fumarate)-first-time
generic.
https://hcpprod.optumrx.com/vgnlive/HCP/Assets/RxNews/New
%20Generics_Minastrin%2024%20Fe_20160527.pdf. (Accessed August 31, 2016).
152. Food and Drug Administration. ANDA approval
letter.
Apotex generic Sprycel.
June 10,
2016http://www.accessdata.fda.gov/drugsatfda_docs
/appletter/2016/202103Orig1s000ltr.pdf. (Accessed
August 31, 2016).
153. Edenbridge Pharmaceuticals. News. June 30, 2016.
http://edenbridgepharma.com/news.php. (Accessed
August 31, 2016).
154. Orexo AB, vs Mylan Pharmaceuticals Inc. and Mylan
Inc..
June
30,
2011.
patentdocs.typepad.com/files/orexo-v-mylan.pdf.
(Accessed August 31, 2016).
155. Orexo.
Interim report January-June 2015.
http://feed.ne.cision.com/wpyfs/00/00/00/00/00/2E/89
/30/wkr0006.pdf. (Accessed August 31, 2016).
156. Anon. Strides Shasun receives USFDA tentative
approval for roflumilast tablets.
June 1, 2016.
http://www.stridesarco.com/pdf/pressrelease/2016/us
fda_tentative_approval_for_roflumilast_tablets.pdf.
(Accessed August 31, 2016).
157. Anon. Vanda patents found valid and infringed in
Fanapt ANDA litigation.
August 25, 2016.
http://www.nasdaq.com/press-release/vandapatents-found-valid-and-infringed-in-fanapt-andalitigation-20160825-00739. (Accessed August 31,
2016).
158. Food and Drug Administration. ANDA approval
letter. Actavis generic Diclegis. August 19, 2016.
http://www.accessdata.fda.gov/drugsatfda_docs/appl
etter/2016/205811Orig1s000ltr.pdf.
(Accessed
August 31, 2016).
159. Johnson LA, Perrone M. Novartis wins US OK for
biosimilar of Amgens Enbrel.
http://www.timesstandard.com/article/zz/20160830/NEWS/160839822.
More. . .
Copyright 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
PharmacistsLetter.com ~ PrescribersLetter.com ~ PharmacyTechniciansLetter.com ~ NursesLetter.com
Cite this document as follows: Professional Resource, Anticipated Availability of First-Time Generics. Pharmacists
Letter/Prescribers Letter. September 2016.
Subscribers to the Letter can get professional resources, like this one,
on any topic covered in any issue by going to PharmacistsLetter.com,
PrescribersLetter.com, PharmacyTechniciansLetter.com, or NursesLetter.com
Detail-Document #250801
This Detail-Document accompanies the related article published in
Azilsartan (Edarbi)
40 mg QDc
40 mg QDc
40 mg QDc
40 mg QDc
Candesartan (Atacand)
4 mg QDa
8 mg QD or
divided BID
16 mg QD or
divided BIDb
16 mg QD or
divided BIDb to
32 mg QD or
divided BID
---
Eprosartan (Teveten)
400 mg QD
600 mg QDL
75 mg QDc
150 mg QD
800 mg QD or
divided BIDd
300 mg QD
---
Irbesartan (Avapro)
800 mg QD or
divided BIDd
300 mg QD
Losartan (Cozaar)
25 mg QDe
Olmesartan (Benicar)
10 mg QD
50 mg QD or
divided BIDn
20 mg QDf
Telmisartan (Micardis)
20 mg QD
40 mg QDg
Valsartan (Diovan)
40 mg QD or
20 mg BIDh
80 mg QDj or
40 mg BIDi,m
100 mg QD or
divided BIDn
20 mg QDf to
40 mg QD
40 mg QDg to
80 mg QD
160 mg QDj
80 mg QD
---
---
---
40 mg QD
---
80 mg QD
---
320 mg QDk,m
--More. . .
a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.
L.
m.
n.
Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical
judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national
organizations. Information and Internet links in this article were current as of the date of publication.
More. . .
Copyright 2009 by Therapeutic Research Center
Pharmacists Letter / Prescribers Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Cite this Detail-Document as follows: Angiotensin receptor blocker (ARB) antihypertensive dose comparison.
Pharmacists Letter/Prescribers Letter 2009 (Full update February 2012);25(8):250801.
Subscribers to Pharmacists Letter and Prescribers Letter can get Detail-Documents, like this one, on any
topic covered in any issue by going to www.pharmacistsletter.com or www.prescribersletter.com
Detail-Document #260301
This Detail-Document accompanies the related article published in
Candesartan
(Atacand)
HTN:
8-32 mg daily in one
or two divided doses1
Hypertension1
Heart Failure1
Diabetic retinopathy:
reduces incidence
(type 1 DM) and
improves mild to
moderate retinopathy
(type 2 DM)2,3
Nephropathy (type 2
DM): reduces
microalbuminuria14
4, 8, 16, 32 mg1
$104.99 (32 mg once
daily)
With HCT (Atacand HCT;
indicated for HTN only;
not for initial therapy; not
recommended if CrCl
<30 mL/min): 16/12.5,
32/12.5,
32/25 mg4
More. . .
Copyright 2010 by Therapeutic Research Center
Pharmacists Letter / Prescribers Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com
Medication
Initial Dosea
Maintenance Dosea
Eprosartan
(Teveten)
400-800 mg daily in
one or two divided
doses5
Irbesartan
(Avapro)
HTN: 150-300 mg
once daily7
Nephropathy (type 2
DM): 300 mg once
daily7
Losartan
(Cozaar, generics)
Continued
CHF:
12.5 mg once daily (not
currently taking an ARB) or
25 mg once daily (switching
FDAApproved
Indicationa
Hypertension5
How Supplied/CostL
Clinical Benefit
ina,h
Hypertension7
Nephropathy
(type 2 DM)7
Nephropathy (type 2
DM): reduces rate of
progression7
HTN:
25-100 mg daily in
one or two divided
doses9
Hypertension9
HTN/LVH:
50-100 mg once daily
(plus HCT if
needed)9
Hypertension
with LVH9
Nephropathy (type 2
DM): 100 mg once
daily9
Nephropathy
(type 2 DM)9
More. . .
Copyright 2010 by Therapeutic Research Center
Pharmacists Letter / Prescribers Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com
Medication
Initial Dosea
Maintenance Dosea
Losartan, cont.
Olmesartan
(Benicar)
20 mg once daily12,g
20-40 mg once
daily12
FDAApproved
Indicationa
Hypertension12
How Supplied/CostL
Clinical Benefit
ina,h
Nephropathy (type 2
DM): reduces rate of
progression9
Type 2 DM: delays
onset of
microalbuminuria,
but with increased
risk of fatal CV
events among
patients with
coronary artery
disease28
5, 20, 40 mg12
$129.32 (40 mg once
daily)
With HCT (Benicar HCT;
not for initial therapy; not
recommended if CrCl <30
mL/min): 20/12.5,
40/12.5,
40/25 mg13
With amlodipine (Azor):
5/20, 10/20, 5/40,
10/40 mg21
With HCT and amlodipine
(Tribenzor; not for initial
therapy; not for volumedepleted patients; avoid if
CrCl <30 mL/min):
20/5/12.5, 40/5/12.5,
40/5/25, 40/10/12.5,
40/10/25 mg22
Telmisartan
(Micardis)
Continued
High CV risk:
reduces risk of CV
events15
Medication
Initial Dosea
Maintenance Dosea
Telmisartan, cont.
inhibitors):
80 mg once daily15,i
CV risk reduction:
80 mg once daily15
FDAApproved
Indicationa
patients unable
to take ACEI15
Clinical Benefit
ina,h
How Supplied/CostL
Nephropathy (type 2
DM): reduces
microalbuminuria,16
slows progression as
well as enalapril,32
and reduces
proteinuria in patients
with HTN29,30
Hemodialysis
patients with CHF:
added to ACEI,
reduces all-cause and
CV mortality, and
heart failure
hospitalization24
Valsartan
(Diovan)
HTN: 80-320 mg
once daily18
Hypertension
CHF: reduces
hospitalization18
CHF: 40-160 mg
twice daily (target
160 mg twice daily)18
Heart Failure
(Class II to IV)
Post-MI: 20-160 mg
twice daily (target
160 mg twice daily)18
Post-MI with
left ventricular
dysfunction/
failure
Continued
Nephropathy (type 2
DM): reduces
microalbuminuria,19
and proteinuria in
patients with HTN30
More. . .
Copyright 2010 by Therapeutic Research Center
Pharmacists Letter / Prescribers Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com
Medication
Valsartan, cont.
Initial Dosea
Maintenance Dosea
FDAApproved
Indicationa
Clinical Benefit
ina,h
How Supplied/CostL
10/320 mg25
With amlodipine and HCT
(Exforge HCT; indicated
for HTN only; not for
initial therapy; not for
volume-depleted patients;
avoid if CrCl
<30 mL/min): 5/160/12.5,
10/160/12.5, 5/160/25,
10/160/25, 10/320/25 mg26
With aliskiren (Valturna;
not for volume-depleted
patients): 150/160,
300/320 mg31
Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A
C
D
Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study
References
1.
More. . .
Copyright 2010 by Therapeutic Research Center
Pharmacists Letter / Prescribers Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com
Pharmacists
Subscribers to Pharmacists Letter and Prescribers Letter can get Detail-Documents, like this one, on any
topic covered in any issue by going to www.pharmacistsletter.com or www.prescribersletter.com